



Biocept Inc.
Investor Relations Department
5810 Nancy Ridge Drive
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: BIOC

Last Trade:	0.69
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	0.01 (+1.696%)
Day Range	0.64 - 0.69
52-Week Range	0.60 - 3.39
Volume	230,209

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests perfor... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 9, 2017*
[Biocept Reports Third Quarter 2017 Financial Results](#)
- Nov 2, 2017*
[Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017](#)
- Oct 18, 2017*
[Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals](#)
- Oct 11, 2017*
[Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board](#)
- Oct 3, 2017*
[Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 28, 2017*
[Annual Report \(10-K\)](#)
- Mar 30, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 14, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 14, 2017*
[Quarterly Report \(10-Q\)](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)